Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 1.430 | 1.430 | 0.000 |
Stocks | 97.810 | 97.810 | 0.000 |
Other | 0.760 | 0.760 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 15.448 | 14.534 |
Price to Book | 2.793 | 2.016 |
Price to Sales | 1.511 | 1.302 |
Price to Cash Flow | 10.069 | 9.063 |
Dividend Yield | 3.340 | 3.332 |
5 Years Earnings Growth | 9.244 | 12.142 |
Name | Net % | Category Average |
---|---|---|
Financial Services | 18.010 | 14.401 |
Healthcare | 17.360 | 13.497 |
Industrials | 16.420 | 20.065 |
Technology | 14.470 | 11.751 |
Consumer Defensive | 10.820 | 9.670 |
Consumer Cyclical | 9.490 | 12.963 |
Utilities | 5.750 | 2.932 |
Communication Services | 4.290 | 7.060 |
Basic Materials | 2.050 | 8.835 |
Energy | 1.330 | 5.715 |
Number of long holdings: 68
Number of short holdings: 2
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 6.53 | 622.6 | +5.67% | |
Novartis | CH0012005267 | 4.27 | 87.68 | +1.11% | |
Relx | GB00B2B0DG97 | 3.18 | 3,617.00 | +0.25% | |
Wolters Kluwer | NL0000395903 | 2.75 | 159.50 | 0.00% | |
Swiss Re | CH0126881561 | 2.65 | 130.35 | +1.44% | |
Allianz | DE0008404005 | 2.62 | 294.20 | -0.14% | |
Inditex | ES0148396007 | 2.57 | 49.510 | +0.14% | |
Deutsche Boerse | DE0005810055 | 2.54 | 221.200 | -1.16% | |
L'Oreal | FR0000120321 | 2.52 | 339.85 | +0.53% | |
Schneider Electric | FR0000121972 | 2.48 | 239.80 | +0.29% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CV Strategiefonds EUR B | 26.13M | 5.89 | 3.35 | 2.91 | ||
AMG Europa A | 20.71M | 10.20 | 0.91 | 4.52 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review